The first two authors contributed equally in the preparation of the manuscript The aim of our study is to evaluate portal and hepatic hemodynamic changes after N-acetylcysteine infusion in patients with systemic sclerosis. In an open-label study 40 patients with Systemic Sclerosis (SSc) were treated with 15mglkg/hour intravenous N-acetylcysteine for 5 consecutive hours in a single day. Hepatic flow volume, congestion index, portal flow volume, resistance index and pulse rate index were measured in each subject before and after infusion. In all patients mean hepatic flow volume (HFV) and mean portal flow volume (PFV) values after the five-hour infusion with NAC increased not significantly. In 22 selected patients with active capillaroscopic pattern, modified Rodnan Total Skin Score (mRTSS) <18 and mild-moderate score to vascular domain of disease severity scale (DSS), mean HFV increased significantly when compared with mean HFV of 18 SSc patients with late capillaroscopic pattern, mRTSS >18 and severe-end stage score to vascular domain of DSS. The results of our study demonstrate that NAC is able to increase HFV and total liver perfusion after a single infusion in SSc patients with low disease activity and severity scores.
Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis affecting the skin and the internal organs (1) . N-acetylcysteine (NAC), a sulfhydryl substance with a powerful antioxidant and cellular detoxifying action, is a precursor of the major antioxidant glutathione. This medical compound was proposed about 50 years ago as a mucolytic agent for chronic pulmonary diseases and it is now used for the treatment of fibrotic lung disease since it restores depleted levels ofpulmonary glutathione, thus improving lung function (2) . It is also used in the treatment of Raynaud's phenomenon (RP) and SSc because of its oxygen free radical scavenging and vasodilatation properties (3) (4) (5) . Recently, it was demonstrated that NAC increases peripheral perfusion in sclerodermic patients with secondary RP (6) .
Conflicting results have been reported about NAC effects on liver. Some authors demonstrated that it improves hemodynamics and oxygen transportation in acute liver failure from different triggering causes and that its addition to interferon-a results in a more effective treatment, but opposite conclusions were observed by other authors (7) (8) .
However, there is clinical evidence that NAC has peripheral vasodilatation properties, but no studies on its hemodynamic effects on human liver exist. Several studies show that NAC administration significantly improves portal flow, hepatic microcirculation, bile composition and bile flow in rabbits after 5 h ofreperfusion and reduces the extent of injury in hepatic steatosis, especially during late phase reperfusion (9) . The decrease of intrahepatic resistance in NAC-treated cirrhotic rats is mainly due to prevention of hepatic fibrogenesis because of NAC anti-oxidative effects together with the decrease of oxidants-related nitro-tyrosilation and the improvement of hepatic endothelial dysfunction (10) .
The aim of our study is to evaluate the effects on portal and hepatic hemadynamics with color Doppler sonography before and after NAC infusion in 40 SSc patients.
MATERIALS AND METHODS

Patients
The study group consisted of 40 patients (3 males and 37 females; mean age 49±15 years) with SSc diagnosed according to the American Rheumatism Association (ACR) criteria (11) who were admitted to the Clinical Immunology Unit of the Sapienza University of Rome. All SSc patients fulfilled the ACR criteria for SSc and were subsequently divided into limited (1cSSc) and diffuse (dcSSc) cutaneous SSc groups according to LeRoy (1) . Table I lists the patients' main baseline epidemiological  and clinical features. Patients already treated with NAC infusion or affected with hypertension, liver or renal failure and treated with anti-hypertensive agents within 3 months previous to enrolment were excluded from the study. Patients treated with prostacyclin analogues within 6 months before enrolment were excluded from the study. Patients with the presence of serum anti-mitochondrial antibodies were excluded from this study even in the absence of liver damage.
Medical Treatment
All the enrolled patients were treated with NAC infusion at a dosage of 15mg/Kg per hour for 5 consecutive hours.
Color Doppler examination
All patients underwent hepatic artery and portal vein sonography before and after the 5-hour treatment with NAe. Patients were examined after an 8-hour fast in a supine position and studied by the same operator using Toshiba Aplio equipment and a convex 3.5 MHz probe. The machine was supported by the relative software which automatically gave us hemodynamic parameter measurements based on the spectral Doppler waveform.
All scans were initially performed in a gray-scale and then using a color Doppler module after obtaining a transverse section at the epigastrium to visualize hepatic artery and portal vein in their longitudinal axis. After hepatic artery and portal vein insonation, the size of sample volume was optimised in each patient on the basis of the vessel's diameter. The results were expressed as a mean of the three Doppler sonography evaluations performed with an angle of insonation between 50°and 60°in order to minimize the casual variability of flow velocity along the course of hepatic artery and portal vem.
Hepatic artery measurements
Hepatic artery was studied after positioning the sample volume near the crossing point of the hepatic artery itself with the portal vein after the splenic artery's origin. Hepatic artery measurements were: diameter expressed in ern, cross-sectional area in cm-, time-averaged mean velocity in ern/sec and hepatic flow volume (HFV) in ml/min, Resistance Index [RI = (systolic velocity -end diastolic velocity)/systolic velocity)] and pulsatility index [PI = (systolic velocity -middle velocity)/systolic velocity)]
Portal vein measurement
After visualizing the portal vein, the Doppler sample volume was placed at the crossing point of the portal vein with the hepatic artery. The following measurements were performed: diameter expressed in em, cross-sectional area (CSA) in em", time-averaged middle velocity in em/sec, portal flow volume (PFV) in ml/min and the congestion index (CI), which was calculated using the formula [CSA (cm 2 ) ] / portal vein middle velocity in accordance with a Moriyasu et al. study (12) .
Nailfold videocapillaroscopy
Nailfold videocapillaroscopy (NVC) was performed by the same operator in each patient before NAC infusion using an optical probe videocapillaroscopy equipped with magnification 100 x contact lens and connected to an image analysis software (Studio Version 8, Pinnacle System, Milan, Italy). Each subject underwent acclimatization for a minimum of 15 min before the nailfold was examined and the room temperature was 20-22°e. The nailfold (distal row) of the second, third, fourth and fifth finger was examined in each patient.
Microvascular alterations, as detected by nailfold videocapillaroscopy (NVC) in patients with SSe, have been re-classified in three different patterns according to Cutolo et al. (13) . The patterns identified within the "SSe pattern" include Early NYC pattern: few enlarged! giant capillaries, few capillary haemorrhages, relatively well-preserved capillary distribution and no evident loss of capillaries; Active NVC pattern: frequent giant capillaries, frequent capillary haemorrhages, moderate loss of capillaries, mild disorganization of the capillary architecture and absent or mild ramified capillaries; Late NVC pattern: irregular enlargement of the capillaries, few or absent giant capillaries and haemorrhages, severe loss of capillaries with extensive avascular areas, disorganization ofthe normal capillary array and ramified! bushy capillaries.
Assessment ofskin thickening and disease activity
Currently, modified Rodnan TSS (mRTSS) is the most used method to asses skin induration in SSe. It is determined at a standardized location of 17 different sites of the body with a standardized pinching method and it is scored from 0 to 3 (14) . Therefore, mRTSS values are significantly correlated with our "gold standard" of disease activity in univariate analysis (15) . Valentini et al. have proposed to modify the original activity index by changing the method used to assess the TSS and using a value ofmRTSS >14. Disease activity in SSe was measured using Valentini's Scleroderma Disease Activity Score (SDAS) (16) which consists of 10 weighted variables: total skin score >14, scleroderma, digital necrosis, arthritis, total lung capacity <80%, erythrocyte sedimentation rate (ESR) >30, hypocomplementemia and change in cardiopulmonary, skin and vascular symptoms in the previous month.
Disease severity scale
Disease severity was measured using Modified Medsger Scleroderma Disease Severity Scale (DSS) (17) . The original scale assessed disease severity in 9 organs or systems, namely general health, peripheral vascular, skin, joint/tendon, muscle and gastrointestinal tract, lungs, heart and kidneys. Each organ/system is scored separately from 0 to 4 depending on whether there is no, mild, moderate, severe, or end-stage involvement. Our patients were divided in relation to vascular domain: history of Raynaud's scored 1 (mild), digital pitting scars scored 2 (moderate), digital ulcerations scored 3 (severe) and digital gangrene scored 4 (end-stage).
Statistical Analysis
Data were collected and processed using STATA Software (College Station, Texas University, USA) 8.0 version. Normal distribution of data was tested by Shapiro-Francia test. All the variables studied resulted normally distributed. Paired Student's t-test was performed to compare differences in observation pre-and post-infusion. Non-paired Student's test was performed to numerical variables. P value less than 0.05 was considered significant.
RESULTS
HFV and PI mean values after a five-hour infusion with NAC increased not significantly in all patients (Table II) , while mean IR values slightly tended to increase although not significantly. PVF and CI mean values decreased not significantly in all patients (Table II) . Hepatic artery and portal vein mean values showed a different trend when related to capillaroscopic pattern, mRTSS or vascular domain of DSS. In fact, mean HFV significantly (p<0.01) increased (0.24±0.13 Lrnin versus 0.36±0.32 LI min) in patients with an early/active capillaroscopic pattern when compared to patients with a late pattern, in which there is a statistically significant reduction of mean HFV (Table III and Fig. 1 ). Furthermore, Raynaud's duration mean is significantly (p<0.005) lower in patients with an early/active capillaroscopic pattern than in those with a late capillaroscopic pattern (9.8±7.7 versus 19.4±8.5).
Mean HFV significantly (p< 0.005) increased (0.26±0.14 Lrnin versus 0.4±0.22 L'min) in patients with mRTSS<14 when compared to those with mRTSS> 14, whose mean HFV significantly decreased (Table III and Fig. 2 ). Besides, patients with an mRTSS<14 showed a significantly (p<0.001) lower SDAS when compared to those with mRTSS >14 (0.78±0.49 versus 3. 13±0.48).
Mean HFV significantly increased (p<0.004) in patients with mild-moderate score to vascular domain of DSS (0.23±0.13 Lrnin versus 0.37±0.24 Lrnin), while it decreased significantly in patients with severe-end stage score (Table III and Fig. 3 ). Patients with mild-moderate score showed a global DSS score significantly lower (p<0.001) when compared to those with severe-end stage score (3.5±0.6 versus 9.1±1.7). Besides, mean DLCo is significantly (p<0.05) lower in patients with mildmoderate vascular score if compared to patients with severe-end stage vascular score (70.6±12.9 versus 57.9±20). Disease duration mean is significantly (p<0.005) lower in patients with mild-moderate vascular score than in those with severe-end stage vascular score (7.4±6.6 versus 15.3±7.6).
Mean PFV remains steady or increases, although not significantly, in patients with active pattern, mRTSS<14 and mild-moderate score to vascular domain of DSS while it decreases not significantly in patients with late pattern, mRTSS<14 and severeend stage score to vascular domain of DSS (Table  IV) . No statistically significative correlation was found between capillaroscopic pattern, mRTSS, DSS and other hemadimamic indexes (RI, PI, CI).
When we examined all the 40 SSc patients as a single group, we did not find any correlation between hepatic artery and portal vein flow volume (HFV, RI, PI, PFV,CI) or SSc subset and E/A ratio.
DISCUSSION
We have previously demonstrated that patients with SSc show a significant increase in portal flow velocity and portal flow volume after infusion with iloprost, a potent peripheral vasodilator (18) . Since NAC treatment has good peripheral vasodilatory effects in patients with systemic sclerosis and Raynaud's phenomenon, we decided to evaluate these properties in liver hemodynamics after its infusion.
In order to obtain a thorough evaluation of liver hemodynamics, we studied both portal vein and Nevertheless, the little increase of mean PFV in patients with early/active capillaroscopic pattern, mRTSS<14 and mild-moderate score to vascular domain ofDSS, total hepatic flow volume (expressed as the sum of mean HFV and mean PFV) increased anyway. In patients with late capillaroscopic pattern, mRTSS >14 and severe-end stage score to vascular domain ofDSS, total hepatic flow volume decreases because of a reduction of both mean HFV and PFV. The rationale for the treatment with NAC in patients with systemic sclerosis is based on its antioxidant properties. It is known that free radicals and oxidative stress may be involved in the pathogenesis of systemic sclerosis (19) (20) . Skin immunohistological studies on patients with systemic sclerosis also demonstrated an increased iNOS expression (21) (22) ; in tum, the ensuing increase in the formation of superoxide anion (23) regulation of reactive oxygen species (ROS) through the NADPH oxidase complex pathway is also essential for fibroblast proliferation and expression of type I collagen genes in patients with systemic sclerosis (4). The relatively minor side effects and the safety of the treatment made NAC available for the treatment of patients with systemic sclerosis (4, 6) . By opposing oxidative stress, NAC ameliorates skin fibroblast functions and probably prevents their contraction in peripheral microcirculation; in the same way, liver microcirculation might benefit from this therapy.
It is known that both hepatic arterial and portal blood flow combine together into the sinusoids which drain into the terminal hepatic venulaes, and that arterial flow progression from the arterial capillaries into the portal sinusoids is regulated by adenosine in a pressure-dependent manner through the action of smooth muscle cells on precapillary sphincters . It has also been clear for many years that a reduction in portal flow results in an increase of hepatic arterial flow (27) (28) (29) . Therefore, the ability of NAC to increase HFV in the absence of a significant decrease in PFV in patients with active capillaroscopic pattern, mRTSS<14 and mild-moderate score to vascular domain of DSS, is very interesting. In fact, NAC might directly act on precapillary sphincters thus favouring their relaxation. NAC's failure to ameliorate hepatic arterial flow in patients with late capillaroscopic patterns, mRTSS > 14 and severe-end stage to vascular domain of DSS, has not been fully understood; perhaps it might be partially explained by smooth muscle cell alteration. Furthermore, NAC was not able to increase PFV in either group of patients and did not seem to be able to act on hepatic stellate cells; in fact, other mediators such as nitric oxide and prostacyclin are involved in the regulation of hepatic stellate cells at the sinusoidal level. However, it cannot be ruled out whether liver microcirculation could have benefited from a longer period of treatment. Increased ROS levels activate hepatic stellate cells to produce profibrotic mediators (29) ; the ensuing phenotypic modification of hepatic stellate cells into myofibroblasts (30) makes them incapable of modulating the vascular intra-hepatic resistance thus favoring liver sinusoidal vasoconstriction. Hence, a prolonged NAC therapy might counteract the effects of the increased ROS levels.
Total hepatic blood flow is approximately 1400 ml/min. PFV represents about 65%, of total hepatic blood flow, while the proper hepatic artery provides 35% of the total hepatic blood flow entering the liver. Flow volume changes of about 140 ml or greater (10% about of total hepatic blood flow) are considered hemodynamically significant (31) (32) .
In conclusion, the results ofour study demonstrate that NAC is able to increase HFV and total liver perfusion after a single infusion in SSc patients with early/active capillaroscopic pattern, mRTSS<14 and mild-moderate score to vascular domain of DSS. Thus, we can hypothesize that NAC is effective in increasing HFV in those patients with low disease activity and severity.
